Drug interactions in dying patients: A retrospective analysis of hospice inpatients in Germany

Drug Safety

Volumn 35, Issue 9, 2012, Pages 745-758

  Frechen, Sebastian ^a   Zoeller, Anna ^a   Ruberg, Klaus ^b,c   Voltz, Raymond ^a   Gaertner, Jan ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b Hospital and Community Pharmacy   (Germany)

^c Working Group Pharmacists of the German Association of Palliative Care   (Germany)

Author keywords

Adverse drug reactions; Drug interactions; Palliative care; Quality of life

Indexed keywords

AMITRIPTYLINE; BISOPROLOL; BUPRENORPHINE; CARBAMAZEPINE; CITALOPRAM; CLOPIDOGREL; DEXAMETHASONE; DIAZEPAM; DIMENHYDRINATE; DIPYRONE; ENALAPRIL MALEATE PLUS HYDROCHLOROTHIAZIDE; FENTANYL; HALOPERIDOL; IBUPROFEN; INSULIN; LEVODOPA; LORAZEPAM; MACROGOL; METOCLOPRAMIDE; MIDAZOLAM; MORPHINE; OMEPRAZOLE; PANTOPRAZOLE; PRESCRIPTION DRUG; RAMIPRIL; SOTALOL; SPIRONOLACTONE; TORASEMIDE; UNINDEXED DRUG; VALSARTAN;

ADULT; AGED; ANALGESIA; ANTICHOLINERGIC EFFECT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; AWARENESS; DATA BASE; DIURESIS; DRUG ANTAGONISM; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; ELECTRONIC MEDICAL RECORD; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GASTROINTESTINAL TOXICITY; GERMANY; HIGH RISK POPULATION; HOSPICE CARE; HOSPITAL PATIENT; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; INFARCTION; KIDNEY DYSFUNCTION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PARKINSON DISEASE; PHYSICIAN; POLYPHARMACY; PRESCRIPTION; PRIORITY JOURNAL; QT PROLONGATION; RISK FACTOR; SEDATION; SEROTONIN SYNDROME; SIDE EFFECT; TERMINAL CARE; TORSADE DES POINTES; ULCEROGENESIS; UPPER GASTROINTESTINAL BLEEDING; WITHDRAWAL SYNDROME;

AGED; AGED, 80 AND OVER; DRUG INTERACTIONS; FEMALE; GERMANY; HOSPICE CARE; HUMANS; INPATIENTS; MALE; PHARMACEUTICAL PREPARATIONS; POLYPHARMACY; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84864975255     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11631280-000000000-00000     Document Type: Article

References (67)

1. Riechelmann RP, Tannock IF, Wang L, et al. Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst 2007; 99 (8): 592-600 (Pubitemid 47073540)
2. van Leeuwen RW, Swart EL, Boom FA, et al. Potential drug interactions and duplicate prescriptions among ambulatory cancer patients: a prevalence study using an advanced screening method. BMC Cancer 2010; 10: 679
3. Girre V, Arkoub H, Puts MT, et al. Potential drug interactions in elderly cancer patients. Crit Rev Oncol Hematol 2011; 78 (3): 220-6
4. van Leeuwen RW, Swart EL, Boven E, et al. Potential drug interactions in cancer therapy: a prevalence study using an advanced screening method.Ann Oncol 2011; 22 (10): 2334-41
5. Lal LS, Zhuang A, Hung F, et al. Evaluation of drug interactions in patients treated with antidepressants at a tertiary care cancer center. Support Care Cancer 2012; 20 (5): 983-9
6. Bernard SA, Bruera E. Drug interactions in palliative care. J Clin Oncol 2000; 18 (8): 1780-99 (Pubitemid 30220558)
7. Gaertner J, Ruberg K, Schlesiger G, et al. Drug interactions in palliative care: it's more than cytochrome P450. Palliat Med. Epub 2011 Jul 7
8. Riechelmann RP, Zimmermann C, Chin SN, et al. Potential drug interactions in cancer patients receiving supportive care exclusively. J Pain Symptom Manage 2008; 35 (5): 535-43
9. Kohler GI, Bode-Boger SM, Busse R, et al. Drug-drug interactions in medical patients: effects of in-hospital treatment and relation to multiple drug use. Int J Clin Pharmacol Ther 2000; 38 (11): 504-13
10. Juurlink DN, Mamdani M, Kopp A, et al. Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA 2003; 289 (13): 1652-8 (Pubitemid 37430270)
11. Miranda V, Fede A, Nobuo M, et al. Adverse drug reactions and drug interactions as causes of hospital admission in oncology. J Pain Symptom Manage 2011; 42 (3): 342-53
12. von Gunten CF. Humpty-dumpty syndrome. Palliat Med 2007; 21 (6): 461-2
13. National Hospice and Palliative Care Organization. Standards of practice for hospice programs. Alexandria (VA): National Hospice and Palliative Care Organization, 2000
14. National Hospice and Palliative Care Organization. NHPCO facts and figures: hospice care in America. 2010 ed. [online]. Available from URL: http://www.nhpco.org/files/public/Statistics-Research/Hospice-Facts-Figures-Oct- 2010.pdf [Accessed 2011 Jun 30]
15. Carlson MD, Morrison RS, Holford TR, et al. Hospice care: what services do patients and their families receive? Health Serv Res 2007; 42 (4): 1672-90 (Pubitemid 47024851)
16. Klaschik E, Nauck F, Radbruch L, et al. Palliative medicine: definitions and principles [in German]. Internist 2000; 41 (7): 606-11 (Pubitemid 30481391)
17. Salloch S, Breitsameter C. Morality and moral conflicts in hospice care: results of a qualitative interview study. J Med Ethics 2010; 36 (10): 588-92
18. van der Sijs H, Aarts J, Vulto A, et al. Overriding of drug safety alerts in computerized physician order entry. J Am Med Inform Assoc 2006; 13 (2): 138-47 (Pubitemid 43332904)
19. Isaac T, Weissman JS, Davis RB, et al. Overrides of medication alerts in ambulatory care. Arch Intern Med 2009; 169 (3): 305-11
20. Mille F, Schwartz C, Brion F, et al. Analysis of overridden alerts in a drug-drug interaction detection system. Int J Qual Health Care 2008; 20 (6): 400-5
21. Hansten PD, Horn JR, Hazlet TK. ORCA: OpeRational ClassificAtion of drug interactions. J Am Pharm Assoc (Wash) 2001; 41 (2): 161-5
22. Zagermann-Muncke P. New classification of interactions: ABDA database as guide in the jungle of interactions [in German]. Pharm Ztg 2009; 154 (1-2): 26-30
23. O'Mahony D, O'Connor MN. Pharmacotherapy at the endof-life. Age Ageing 2011; 40 (4): 419-22
24. Holmes HM, Hayley DC, Alexander GC, et al. Reconsidering medication appropriateness for patients late in life. Arch Intern Med 2006; 166 (6): 605-9
25. Riechelmann RP, Krzyzanowska MK, Zimmermann C. Futile medication use in terminally ill cancer patients. Support Care Cancer 2009; 17 (6): 745-8
26. Fede A, Miranda M, Antonangelo D, et al. Use of unnecessary medications by patients with advanced cancer: cross-sectional survey. Support Care Cancer 2011; 19 (9): 1313-8
27. Harrington CJ, Zaydfudim V. Buprenorphine maintenance therapy hinders acute pain management in trauma. Am Surg 2010; 76 (4): 397-9
28. PrestonKL, BigelowGE, Liebson IA. Butorphanol-precipitated withdrawal in opioid-dependent human volunteers. J Pharmacol Exp Ther 1988; 246 (2): 441-8
29. Oifa S, Sydoruk T, White I, et al. Effects of intravenous patient-controlled analgesia with buprenorphine and morphine alone and in combination during the first 12 postoperative hours: a randomized, double-blind, four-arm trial in adults undergoing abdominal surgery. Clin Ther 2009; 31 (3): 527-41
30. Kress HG. Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine. Eur J Pain 2009; 13 (3): 219-30
31. Lertxundi U, Peral J, Mora O, et al. Antidopaminergic therapy for managing comorbidities in patients with Parkinson's disease. Am J Health Syst Pharm 2008; 65 (5): 414-9 (Pubitemid 351358342)
32. Cuisset T, Frere C, Quilici J, et al. Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study. J Am Coll Cardiol 2009; 54 (13): 1149-53
33. Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol 2006; 61 (3): 246-55 (Pubitemid 43382623)
34. Lyseng-Williamson KA. Levetiracetam: a review of its use in epilepsy. Drugs 2011; 71 (4): 489-514
35. Semel D, Murphy TK, Zlateva G, et al. Evaluation of the safety and efficacy of pregabalin in older patients with neuropathic pain: results from a pooled analysis of 11 clinical studies. BMC Fam Pract 2010; 11: 85
36. Haverkamp W, Breithardt G, Camm AJ, et al. The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. Cardiovasc Res 2000; 47 (2): 219-33 (Pubitemid 30625285)
37. Shah RR. Drug-induced QT interval prolongation: regulatory perspectives and drug development. Ann Med 2004; 36 Suppl. 1: 47-52 (Pubitemid 38669924)
38. Shephard DA. Principles and practice of palliative care. Can Med Assoc J 1977; 116 (5): 522-6
39. Wilcock A, Beattie JM. Prolonged QT interval and methadone: implications for palliative care. Curr Opin Support Palliat Care 2009; 3 (4): 252-7
40. Flockhart DA, Desta Z, Mahal SK. Selection of drugs to treat gastro-oesophageal reflux disease: the role of drug interactions. Clin Pharmacokinet 2000; 39 (4): 295-309
41. Glare PA, Dunwoodie D, Clark K, et al. Treatment of nausea and vomiting in terminally ill cancer patients. Drugs 2008; 68 (18): 2575-90
42. Harris DG. Nausea and vomiting in advanced cancer. Br Med Bull 2010; 96: 175-85
43. Davis MP, Hallerberg G. A systematic review of the treatment of nausea and/or vomiting in cancer unrelated to chemotherapy or radiation. J Pain Symptom Manage 2010; 39 (4): 756-67
44. Weschules DJ. Tolerability of the compound ABHR in hospice patients. J Palliat Med 2005; 8 (6): 1135-43 (Pubitemid 43010545)
45. Wilens TE, Stern TA, O'Gara PT. Adverse cardiac effects of combined neuroleptic ingestion and tricyclic antidepressant overdose. J Clin Psychopharmacol 1990; 10 (1): 51-4 (Pubitemid 20096224)
46. Ness J, Hoth A, Barnett MJ, et al. Anticholinergic medications in community-dwelling older veterans: prevalence of anticholinergic symptoms, symptom burden, and adverse drug events. Am J Geriatr Pharmacother 2006; 4 (1): 42-51
47. Tune LE. Anticholinergic effects of medication in elderly patients. J Clin Psychiatry 2001; 62 Suppl. 21: 11-4 (Pubitemid 32937572)
48. Moore AR, O'Keeffe ST. Drug-induced cognitive impairment in the elderly. Drugs Aging 1999; 15 (1): 15-28 (Pubitemid 29358484)
49. Candy M, Jones L, Williams R, et al. Psychostimulants for depression. CochraneDatabase SystRev 2008; (2): CD006722
50. Mishra S, Bhatnagar S, Nirvani Goyal G, et al. A comparative efficacy of amitriptyline, gabapentin, and pregabalin in neuropathic cancer pain: a prospective randomized double-blind placebo-controlled study. Am J Hosp Palliat Care 2012; 29 (3): 177-82
51. Reilly JG, Ayis SA, Ferrier IN, et al. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 2000; 355 (9209): 1048-52 (Pubitemid 30162807)
52. Piper JM, Ray WA, Daugherty JR, et al. Corticosteroid use and peptic ulcer disease: role of nonsteroidal antiinflammatory drugs. Ann Intern Med 1991; 114 (9): 735-40
53. Simon ST, Bausewein C. Management of refractory breathlessness in patients with advanced cancer. Wien Med Wochenschr 2009; 159 (23-24): 591-8
54. Shih A, Jackson 2nd KC. Role of corticosteroids in palliative care. J Pain Palliat Care Pharmacother 2007; 21 (4): 69-76 (Pubitemid 47585225)
55. Gannon C, Dando N. Dose-sensitive steroid-induced hyperglycaemia. Palliat Med 2010; 24 (7): 737-9
56. Christensen RC, Byerly MJ. Mandibular dystonia associated with the combination of sertraline and metoclopramide [letter]. J Clin Psychiatry 1996; 57 (12): 596 (Pubitemid 27056908)
57. Fisher AA, Davis MW. Serotonin syndrome caused by selective serotonin reuptake-inhibitors-metoclopramide interaction. Ann Pharmacother 2002; 36 (1): 67-71 (Pubitemid 34052947)
58. Jackson N, Doherty J, Coulter S. Neuropsychiatric complications of commonly used palliative care drugs. Postgrad Med J 2008; 84 (989): 121-6; quiz 5 (Pubitemid 351498008)
59. Vandraas KF, Spigset O, Mahic M, et al. Non-steroidal anti-inflammatory drugs: use and co-treatment with potentially interacting medications in the elderly. Eur J Clin Pharmacol 2010; 66 (8): 823-9
60. Schug SA, Manopas A. Update on the role of non-opioids for postoperative pain treatment. Best Pract Res Clin Anaesthesiol 2007; 21 (1): 15-30 (Pubitemid 46478025)
61. Portenoy RK. Treatment of cancer pain. Lancet 2011; 377 (9784): 2236-47
62. McNicol E, Strassels SA, Goudas L, et al. NSAIDS or paracetamol, alone or combined with opioids, for cancer pain. Cochrane Database Syst Rev 2005; (1): CD005180
63. Wilcock A, Thomas J, Frisby J, et al. Potential for drug interactions involving cytochrome P450 in patients attending palliative day care centres: a multicentre audit. Br J Clin Pharmacol 2005; 60 (3): 326-9 (Pubitemid 41224142)
64. Haddad A, Davis M, Lagman R. The pharmacological importance of cytochrome CYP3A4 in the palliation of symptoms: review and recommendations for avoiding adverse drug interactions. Support Care Cancer 2007; 15 (3): 251-7 (Pubitemid 46295205)
65. Regnard C, Hunter A. Increasing prescriber awareness of drug interactions in palliative care. J Pain Symptom Manage 2005; 29 (3): 219-21 (Pubitemid 40386737)
66. O'Connor M, Pugh J, Jiwa M, et al. The palliative care interdisciplinary team: where is the community pharmacist? J Palliat Med 2011; 14 (1): 7-11
67. Borgsteede SD, Rhodius CA, De Smet PA, et al. The use of opioids at the end of life: knowledge level of pharmacists and cooperation with physicians. Eur J Clin Pharmacol 2011; 67 (1): 79-89